Pretreatment CT-based machine learning radiomics model to predict response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy.

被引：0
|
作者：
Shang, Changzhen [1 ]
Hua, Yonglin [1 ]
Chen, Yajin [1 ]
Zhuang, Hongkai [1 ]
机构：
[1] Sun Yat sen Univ, Sun Yat sen Mem Hosp, Dept Hepatobiliary Surg, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 23_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.23_suppl.94
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：94 / 94
页数：1
相关论文
共 50 条
  • [21] Machine learning-based MRI radiomics predicts overall survival of unresectable hepatocellular carcinoma undergoing transarterial chemoembolization plus PD-(L)1 inhibitors and molecular targeted therapy
    Zhong, B-Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S662 - S662
  • [22] Lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma: A large real-world study from two centers.
    Yang, Xu
    Chen, Bowen
    Wang, Yanyu
    Wang, Yunchao
    Long, Junyu
    Zhang, Nan
    Xue, Jinnan
    Xun, Ziyu
    Zhang, Linzhi
    Cheng, Jiamin
    Lei, Jin
    Pan, Jie
    Hu, Ke
    Guan, Mei
    Huo, Li
    Mao, Yilei
    Sang, Xinting
    Lu, Yinying
    Zhao, Hai-Tao
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16155 - E16155
  • [23] The Role of Timing of Progression and Early Salvage Surgery in Unresectable Hepatocellular Carcinoma Treated with TACE Plus TKIs and PD-1 Inhibitors
    Li, Xingzhi
    Tang, Zhihong
    Pang, Qingqing
    Wang, Xiaobo
    Bai, Tao
    Chen, Jie
    Wei, Meng
    Wei, Tao
    Li, Lequn
    Wu, Feixiang
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 1641 - 1652
  • [24] Predicting Pathological Response of Neoadjuvant Conversion Therapy for Hepatocellular Carcinoma Patients Using CT-Based Radiomics Model
    Wen, Haoxiang
    Liang, Ruiming
    Liu, Xiaofei
    Yu, Yang
    Lin, Shuirong
    Song, Zimin
    Huang, Yihao
    Yu, Xi
    Chen, Shuling
    Chen, Lili
    Qian, Baifeng
    Shen, Jingxian
    Xiao, Han
    Shen, Shunli
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 2145 - 2157
  • [25] Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study
    Qu, Shuping
    Zhang, Xiaobing
    Wu, Yutian
    Meng, Yan
    Pan, Hongyu
    Fang, Qiang
    Hu, Lei
    Zhang, Jin
    Wang, Ruoyu
    Wei, Lixin
    Wu, Dong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [26] Changes in systemic immune-inflammation index (SII) predict the prognosis of patients with hepatitis B-related hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors
    Yao, Yang
    Zhang, Minyue
    Liu, Di
    Liu, Xiaoni
    Li, Quanwei
    Wang, Xiaojun
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025, 27 (03): : 1155 - 1165
  • [27] Early tumor marker decrease to predict the efficacy of combination therapy with lenvatinib plus anti-PD-1 antibodies in unresectable hepatocellular carcinoma (uHCC).
    Sun, Hui-Chuan
    Zhu, Xiao-Dong
    Huang, Cheng
    Shen, Ying-Hao
    Ge, Ning-Ling
    Zhu, Jin-Jin
    Xu, Bin
    Chen, Yi
    Li, Mei-Ling
    Zhou, Jian
    Fan, Jia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [28] Neutrophil-to-Lymphocyte Ratio and Early Tumor Shrinkage as Predictive Biomarkers in Unresectable Hepatocellular Carcinoma Patients Treated With Lenvatinib, PD-1 Inhibitors, in Combination With TACE
    Qu, Shuping
    Wu, Dong
    Hu, Zhiming
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [29] Neutrophil-to-Lymphocyte Ratio and Early Tumor Shrinkage as Predictive Biomarkers in Unresectable Hepatocellular Carcinoma Patients Treated With Lenvatinib, PD-1 Inhibitors, in Combination With TACE
    Qu, Shuping
    Wu, Dong
    Hu, Zhiming
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [30] Tumor radiomic features on pretreatment MRI to predict response to lenvatinib plus an anti-PD-1 antibody in advanced hepatocellular carcinoma: a multicenter study
    Xu, Bin
    Dong, Sanyuan
    Bai, Xue-Li
    Song, Tian-Qiang
    Zhang, Bo-Heng
    Zhou, Le-Du
    Chen, Yong-Jun
    Zeng, Zhi-Ming
    Wang, Kui
    Zhao, Hai-Tao
    Lu, Na
    Zhang, Wei
    Li, Xu-Bin
    Zheng, Su-Su
    Long, Guo
    Yang, Yu-Chen
    Huang, Hua-Sheng
    Huang, Lan-Qing
    Wang, Yun-Chao
    Liang, Fei
    Zhu, Xiao-Dong
    Huang, Cheng
    Shen, Ying-Hao
    Zhou, Jian
    Zeng, Meng-Su
    Fan, Jia
    Rao, Sheng-Xiang
    Sun, Hui-Chuan
    LIVER CANCER, 2023, 12 (03) : 262 - 276
12345